The Scientist - USA (2021-02)

Parkinson’s disease is the second most common neurodegenerative disorder. It is characterized by misfolded alpha-synuclein deposits and dopaminergic neuron

death, which lead to progressive motor impairment and disability. Despite extensive efforts, there are no disease-modifying therapies available for Parkinson’s

disease or related “alpha-synucleinopathies.” Glia may represent a source of untapped therapeutic potential.

In this webinar sponsored by BioLegend, Abby Olsen, Associate Neurologist at Brigham and Women’s Hospital, discusses how an innovative Drosophila model

helps explore the genetic contribution of glia to Parkinson’s disease pathogenesis. She reviews how forward genetic screens identify novel glial genes and

potential therapeutic targets for downstream investigation in mammalian systems and patients.

ABBY OLSEN, MD, PHD

Associate Neurologist

Brigham and Women’s Hospital

Instructor in Neurology

Harvard Medical School

WATCH NOW!

http://www.the-scientist.com/Glia-in-Parkinsons-Disease

TOPICS COVERED

• A Drosophila model of neurodegenerative alpha-
  synucleinopathies


• The role of alpha-synuclein in glia


• The unique transcriptional signature of alpha-synuclein in
  glia in Parkinson’s disease


• The pathogenic effects and mechanisms of Parkinson’s
  disease candidate genes when expressed in the glia


• Genetic screens to identify novel glial genes and potential
  therapeutic targets

ORIGINALLY AIRED

THURSDAY, SEPTEMBER 17, 2020

ONDEMAND Unpacking the Genetic Contribution of Glia to Parkinson’s Disease

WEBINAR SPONSORED BY

Many immunologists are looking at T cells to understand the potential for lasting immunity to SARS-CoV-2. In this multisponsored webinar from The

Scientist, Alessandro Sette and Shane Crotty will present the latest findings in T cell function following SARS-CoV-2 infection and the implications for

vaccine development and lasting immune memory.

ALESSANDRO SETTE, PHD

Professor

Center for Autoimmunity and Inflammation

Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology

SHANE CROTTY, PHD

Professor

Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology

WATCH NOW!

http://www.the-scientist.com

/a-new-hope-t-cells-lasting-protection-against-sars-cov-2

TOPICS COVERED

• CD4+ and CD8+ T cell recognition of SARS-CoV-2 sequences
  in unexposed individuals and potential cross-reactivity with
  common cold coronaviruses


• Implications of the T cell response against SARS-CoV-2 for
  vaccine design and viral escape


• How the nature of the acute immune response correlates
  with COVID-19 severity


• Factors affecting SARS-CoV-2 immune response duration
  and memory

ORIGINALLY AIRED

TUESDAY, JANUARY 12, 2021

ONDEMAND T Cells: A New Hope for Lasting Protection Against SARS-CoV-2

WEBINAR SPONSORED BY